Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program in The Netherlands
Anti-Cancer Drugs , Volume 11 - Issue 4 p. 249- 255
The aims of this study were to evaluate the efficacy and safety of docetaxel (Taxotere1) in patients with progressive locally advanced or metastatic breast cancer, previously treated with at least one chemotherapy regimen, and the effect of the number of previous chemotherapy lines on response rate, progression-free survival and overall survival. Two-hundred and fifty-three patients from 10 hospitals in The Netherlands received docetaxel as part of a compassionate use program. The majority had received prior anthracyclinecontaining chemotherapy (84.2%). The recommended starting dose was 100 mg/m2 i.v. every 3 weeks. All patients received corticosteroid premedication. Two-hundred and thirty patients were evaluable for response. The overall response rates (ORR) to docetaxel when used as second-, third- or fourth-line treatment were, respectively, 40.2, 26.0 and 34.6% (p value 0.30). The median progression-free survival for this population was 4.9 months and the median overall survival of the whole group was 8.5 months, and both were not related to the number of previous chemotherapy regimens (p value, respectively, 0.71 and 0.16). The toxicity of docetaxel was manageable and neutropenia was the most frequently noted toxicity. This study confirms that docetaxel is an active cytotoxic agent in pretreated patients with progressive locally advanced or metastatic breast cancer and is still active when used as third- or fourth-line treatment.
|Breast cancer, Chemotherapy, Docetaxel, Overall survival, Progression-free survival, Toxicity|
|Organisation||Department of Medical Oncology|
Kruijtzer, C.M.F, Verweij, J, Schellens, J.H.M, Beijnen, J.H, Pronk, L.C, Bo, M, … Ten Bokkel Huinink, W.W. (2000). Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program in The Netherlands. Anti-Cancer Drugs, 11(4), 249–255. doi:10.1097/00001813-200004000-00004